Latest & greatest articles for epilepsy

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on epilepsy or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on epilepsy and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for epilepsy

141. Lamotrigine add-on for drug-resistant partial epilepsy. (PubMed)

Lamotrigine add-on for drug-resistant partial epilepsy. This is an updated version of the Cochrane review published in The Cochrane Library 2010, Issue 1.Epilepsy is a common neurological disorder, affecting almost 0.5% to 1% of the population. For nearly 30% of these people, their epilepsy is refractory to currently available drugs. Pharmacological treatment remains the first choice to control epilepsy. Lamotrigine is one of the newer antiepileptic drugs and is the topic of this review (...) for people with refractory partial epilepsy.For the previous version of the review, the authors searched the Cochrane Epilepsy Group Specialized Register (January 2010), the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library 2010, Issue 1), MEDLINE (1950 to January 2010), and reference lists of articles.For this update, we searched the Cochrane Epilepsy Group Specialized Register (28 May 2015), CENTRAL (The Cochrane Library 2015, Issue 4), MEDLINE (Ovid, 1946 to May 2015

Full Text available with Trip Pro

2016 Cochrane

142. Briviact (brivaracetam) - To treat partial onset seizures in patients age 16 years and older with epilepsy.

Briviact (brivaracetam) - To treat partial onset seizures in patients age 16 years and older with epilepsy. Drug Approval Package: Briviact (brivaracetam) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Briviact (brivaracetam) Company: UCB, Inc. Application No.: 205836, 205837 & 205838 Approval Date: February 18, 2016 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF

2016 FDA - Drug Approval Package

143. Contraception for women with epilepsy: counseling, choices, and concerns (PubMed)

Contraception for women with epilepsy: counseling, choices, and concerns Approximately 50% of all pregnancies in women with epilepsy (WWE) occur unplanned. This is worrying, given the increased occurrence of obstetrical complications in WWE, including the risk of seizures and their possible consequences for both the mother and the unborn child. Hormonal contraception is usually regarded as highly effective, but it is subject to numerous bidirectional drug interactions with several antiepileptic

Full Text available with Trip Pro

2016 Open access journal of contraception

144. Melatonin as add-on treatment for epilepsy. (PubMed)

Melatonin as add-on treatment for epilepsy. This is an updated version of the original Cochrane review published in Issue 6, 2012.Epilepsy is one of the most common chronic neurological disorders. Despite the plethora of antiepileptic drugs (AEDs) currently available, 30% of people continue having seizures. This group of people requires a more aggressive treatment, since monotherapy, the first choice scheme, fails to control seizures. Nevertheless, polytherapy often results in a number (...) the Cochrane Epilepsy Group's Specialized Register (12 January 2016), the Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO, 12 January 2016), and MEDLINE (Ovid, 11 January 2016). We searched the bibliographies of any identified study for further references. We handsearched selected journals and conference proceedings. We applied no language restrictions. In addition, we contacted melatonin manufacturers (i.e. Nathura) and original investigators

Full Text available with Trip Pro

2016 Cochrane

145. Ketogenic diet and other dietary treatments for epilepsy. (PubMed)

Ketogenic diet and other dietary treatments for epilepsy. The ketogenic diet (KD), being high in fat and low in carbohydrates, has been suggested to reduce seizure frequency. It is currently used mainly for children who continue to have seizures despite treatment with antiepileptic drugs. Recently, there has been interest in less restrictive KDs including the modified Atkins diet (MAD) and the use of these diets has extended into adult practice.To review the evidence for efficacy (...) and tolerability from randomised controlled trials regarding the effects of KD and similar diets.We searched the Cochrane Epilepsy Group's Specialized Register (30 March 2015), the Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO, 30 March 2015), MEDLINE (Ovid, 30 March 2015), ClinicalTrials.gov (30 March 2015) and the WHO International Clinical Trials Registry Platform (ICTRP, 30 March 2015). We imposed no language restrictions. We checked

Full Text available with Trip Pro

2016 Cochrane

146. Care delivery and self management strategies for adults with epilepsy. (PubMed)

Care delivery and self management strategies for adults with epilepsy. Researchers have criticised epilepsy care for adults for its lack of impact, stimulating the development of various service models and strategies to respond to perceived inadequacies.To assess the effects of any specialised or dedicated intervention beyond that of usual care in adults with epilepsy.For the latest update of this review, we searched the Cochrane Epilepsy Group Specialized Register (9 December 2013 (...) ), the Cochrane Central Register of Controlled Trials (CENTRAL) (2013, Issue 11), MEDLINE (1946 to June 2013), EMBASE (1988 to June 2013), PsycINFO (1887 to December 2013) and CINAHL (1937 to December 2013). In addition, we contacted experts in the field to seek information on unpublished and ongoing studies, checked the websites of epilepsy organisations and checked the reference lists of included studies.We included randomised controlled trials, controlled or matched trials, cohort studies or other

Full Text available with Trip Pro

2016 Cochrane

147. Epilepsy. (PubMed)

Epilepsy. This issue provides a clinical overview of epilepsy, focusing on diagnosis, prevention, treatment, and further considerations. The content of In the Clinic is drawn from the clinical information and education resources of the American College of Physicians (ACP), including MKSAP (Medical Knowledge and Self-Assessment Program). Annals of Internal Medicine editors develop In the Clinic in collaboration with the ACP's Medical Education and Publishing divisions and with the assistance

2016 Annals of Internal Medicine

148. Cause of death and predictors of mortality in a community-based cohort of people with epilepsy (PubMed)

Cause of death and predictors of mortality in a community-based cohort of people with epilepsy The risk of premature mortality is increased in people with epilepsy. The reasons for this and how it may relate to epilepsy etiology remain unclear.The National General Practice Study of Epilepsy is a prospective, community-based cohort that includes 558 people with recurrent unprovoked seizures of whom 34% died during almost 25 years of follow-up. We assessed the underlying and immediate causes (...) of death and their relationship to epilepsy etiology. Psychiatric and somatic comorbidities of epilepsy as predictors of mortality were scrutinized using adjusted Cox proportional hazards models.The 3 most common underlying causes of death were noncerebral neoplasm, cardiovascular, and cerebrovascular disease, accounting for 59% (111/189) of deaths, while epilepsy-related causes (e.g., sudden unexplained death in epilepsy) accounted for 3% (6/189) of deaths. In 23% (43/189) of individuals

Full Text available with Trip Pro

2016 EvidenceUpdates

149. Cohort study: Rate of epilepsy in people with autism and the rate of autism in people with epilepsy are high

Cohort study: Rate of epilepsy in people with autism and the rate of autism in people with epilepsy are high Rate of epilepsy in people with autism and the rate of autism in people with epilepsy are high | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Rate of epilepsy in people with autism and the rate of autism in people with epilepsy are high Article Text Prognosis Cohort study Rate of epilepsy in people with autism and the rate

2016 Evidence-Based Medicine (Requires free registration)

150. Epilepsy in Pregnancy

Epilepsy in Pregnancy Epilepsy in Pregnancy Green-top Guideline No. 68 June 2016 Endorsed by:Epilepsy in Pregnancy This is the first edition of this guideline, produced by the Royal College of Obstetricians and Gynaecologists (RCOG) and endorsed by the following organisations: Association of British Neurologists, Epilepsy Action, Royal College of General Practitioners, Royal College of Midwives and the Royal College of Physicians. Executive summary of recommendations Diagnosis of epilepsy What (...) aspects of diagnosis are specific to pregnancy and the puerperium, including the definition of seizures for the obstetrician? The diagnosis of epilepsy and epileptiform seizures should be made by a medical practitioner with expertise in epilepsy, usually a neurologist. Women with a history of epilepsy who are not considered to have a high risk of unprovoked seizures can be managed as low-risk women in pregnancy. What is the importance of classifying seizure type and epilepsy syndrome? Women

2016 Royal College of Obstetricians and Gynaecologists

151. Care delivery and self management strategies for children with epilepsy. (PubMed)

Care delivery and self management strategies for children with epilepsy. Epilepsy care for children has been criticised for its lack of impact. Various service models and strategies have been developed in response to perceived inadequacies in care provision for children and their families.To compare the effectiveness of any specialised or dedicated intervention for the care of children with epilepsy and their families to the effectiveness of usual care.We searched the Cochrane Epilepsy Group (...) Specialized Register (9 December 2013), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, 2013,Issue 11), MEDLINE (1946 to June week 2, 2013), EMBASE (1988 to week 25, 2013), PsycINFO (1887 to 11 December 2013) and CINAHL Plus (1937 to 11 December 2013). In addition, we contacted experts in the field to seek information on unpublished and ongoing studies, checked the websites of epilepsy organisations and checked the reference lists of included studies.We included

Full Text available with Trip Pro

2015 Cochrane

152. Topiramate monotherapy for juvenile myoclonic epilepsy. (PubMed)

Topiramate monotherapy for juvenile myoclonic epilepsy. Topiramate is a newer broad-spectrum of antiepileptic drug (AED). Some studies have shown the benefits of topiramate monotherapy in the treatment of juvenile myoclonic epilepsy (JME). However, there are no current systematic reviews to determine the efficacy and tolerability of topiramate monotherapy in people with JME.To determine the efficacy and tolerability of topiramate monotherapy in the treatment of JME.We searched the Cochrane (...) Epilepsy Group Specialized Register (2 November 2015), the Cochrane Central Register of Controlled Trials (CENTRAL via the Cochrane Register of Studies CRSO, 2 November 2015), MEDLINE (Ovid, 2 November 2015), EMBASE (1 July 2015) and ClinicalTrials.gov (2 November 2015). In an effort to identify further published, unpublished and ongoing trials, we searched ongoing trials registers, reference lists and relevant conference proceedings, and contacted authors and pharmaceutical companies.We included

2015 Cochrane

153. Interventions for psychotic symptoms concomitant with epilepsy. (PubMed)

Interventions for psychotic symptoms concomitant with epilepsy. This is an updated version of the original Cochrane review published in Issue 4, 2008.People suffering from epilepsy have an increased risk of experiencing psychotic symptoms. The psychotic syndromes associated with epilepsy have generally been classified as ictal, postictal, and interictal psychosis. Anticonvulsant drugs have been reported to precipitate psychosis. Moreover, all antipsychotic drugs have the propensity to cause (...) paroxysmal electroencephalogram abnormalities and induce seizures.To evaluate the benefits of interventions used to treat clinically significant psychotic symptoms occurring in people with epilepsy with regard to global improvement, changes in mental state, hospitalization, behavior, quality of life, effect on the frequency of seizures, and interaction with antiepileptic drugs.We searched the Cochrane Epilepsy Group's Specialized Register (23 March 2015), the Cochrane Central Register of Controlled

Full Text available with Trip Pro

2015 Cochrane

154. Cannabinoids in the Treatment of Epilepsy. (PubMed)

Cannabinoids in the Treatment of Epilepsy. 26672645 2016 01 08 2018 12 02 1533-4406 374 1 2016 01 07 The New England journal of medicine N. Engl. J. Med. Cannabinoids in the Treatment of Epilepsy. 94-5 10.1056/NEJMc1512758 Friedman Daniel D Devinsky Orrin O eng Letter Comment 2015 12 16 United States N Engl J Med 0255562 0028-4793 0 Anticonvulsants 0 Cannabinoids 0 Medical Marijuana AIM IM N Engl J Med. 2015 Sep 10;373(11):1048-58 26352816 N Engl J Med. 2016 Jan 7;374(1):94 26672646 Animals (...) Anticonvulsants therapeutic use Cannabinoids therapeutic use Epilepsy drug therapy Humans Medical Marijuana therapeutic use 2015 12 18 6 0 2015 12 18 6 0 2016 1 9 6 0 ppublish 26672645 10.1056/NEJMc1512758 10.1056/NEJMc1512758#SA2

2015 NEJM

155. Cannabinoids in the Treatment of Epilepsy. (PubMed)

Cannabinoids in the Treatment of Epilepsy. 26672646 2016 01 08 2018 12 02 1533-4406 374 1 2016 01 07 The New England journal of medicine N. Engl. J. Med. Cannabinoids in the Treatment of Epilepsy. 94 10.1056/NEJMc1512758 Killestein Joep J eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anticonvulsants 0 Cannabinoids 0 Medical Marijuana AIM IM N Engl J Med. 2015 Sep 10;373(11):1048-58 26352816 N Engl J Med. 2016 Jan 7;374(1):94-5 26672645 Animals Anticonvulsants therapeutic use (...) Cannabinoids therapeutic use Epilepsy drug therapy Humans Medical Marijuana therapeutic use 2015 12 18 6 0 2015 12 18 6 0 2016 1 9 6 0 ppublish 26672646 10.1056/NEJMc1512758 10.1056/NEJMc1512758#SA1

Full Text available with Trip Pro

2015 NEJM

156. Losigamone add-on therapy for partial epilepsy. (PubMed)

Losigamone add-on therapy for partial epilepsy. Epilepsy is a common neurologic disorder, affecting approximately 50 million people worldwide; nearly a third of these people are not well controlled by a single antiepileptic drug (AED) and usually require treatment with a combination of two or more AEDs. In recent years, many newer AEDs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review. This is an update (...) of a Cochrane review first published in 2012 (Cochrane Database of Systematic Reviews 2012, Issue 6).To investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.We searched the Cochrane Epilepsy Group Specialized Register (16 February 2015), the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library 16 February 2015) and MEDLINE (Ovid, 1946 to 16 February 2015). We searched trials registers and contacted the manufacturer of losigamone

2015 Cochrane

157. Subpial transection surgery for epilepsy. (PubMed)

Subpial transection surgery for epilepsy. Nearly 30% of patients with epilepsy continue to have seizures in spite of using several antiepileptic drug (AED) regimens. Such patients are regarded as having refractory, or uncontrolled, epilepsy. No definition of uncontrolled, or medically refractory, epilepsy has been universally accepted, but for the purposes of this review, we will consider seizures as drug resistant if they have failed to respond to a minimum of two AEDs. It is believed (...) that early surgical intervention may prevent seizures at a younger age, which, in turn, may improve the intellectual and social status of children. Many types of surgery are available for treatment of refractory epilepsy; one such procedure is known as subpial transection.To determine the benefits and adverse effects of subpial transection for partial-onset seizures and generalised tonic-clonic seizures in children and adults.We searched the Cochrane Epilepsy Group Specialised Register (29 June 2015

Full Text available with Trip Pro

2015 Cochrane

158. The Importance of Checking Impedance: Misinterpretation of Deep Brain Stimulation Dysfunction as Epilepsy (PubMed)

The Importance of Checking Impedance: Misinterpretation of Deep Brain Stimulation Dysfunction as Epilepsy 30363556 2019 02 26 2330-1619 3 2 2016 Mar-Apr Movement disorders clinical practice Mov Disord Clin Pract The Importance of Checking Impedance: Misinterpretation of Deep Brain Stimulation Dysfunction as Epilepsy. 206-208 10.1002/mdc3.12267 Wolf Marc E ME Department of Neurology Universitätsmedizin Mannheim University of Heidelberg Mannheim Germany. Blahak Christian C Department of Neurology (...) Universitätsmedizin Mannheim University of Heidelberg Mannheim Germany. Krauss Joachim K JK Department of Neurosurgery Hannover Medical School Hannover Germany. eng Case Reports 2015 11 27 United States Mov Disord Clin Pract 101630279 2330-1619 deep brain stimulation dystonia epilepsy globus pallidus internus side effects 2015 05 28 2015 09 01 2015 09 04 2018 10 27 6 0 2015 11 27 0 0 2015 11 27 0 1 epublish 30363556 10.1002/mdc3.12267 MDC312267 PMC6178714 N Engl J Med. 2006 Nov 9;355(19):1978-90 17093249 Lancet

Full Text available with Trip Pro

2015 Movement disorders clinical practice

159. Hospital-Diagnosed Pertussis Infection in Children and Long-term Risk of Epilepsy. (PubMed)

Hospital-Diagnosed Pertussis Infection in Children and Long-term Risk of Epilepsy. Pertussis is associated with encephalopathy and seizures in infants. However, the risk of childhood epilepsy following pertussis is unknown.To examine whether pertussis is associated with the long-term risk of epilepsy.We used individually linked data from population-based medical registries covering all Danish hospitals to identify a cohort of all patients with pertussis born between 1978 and 2011, followed up (...) through 2011. We used the Civil Registration System to identify 10 individuals from the general population for each patient with pertussis, matched on sex and year of birth.Inpatient or hospital-based outpatient diagnosis of pertussis.Cumulative incidence and hazard ratio of time to hospital-based epilepsy diagnosis (pertussis cohort vs general population cohort), adjusted for birth year, sex, maternal history of epilepsy, presence of congenital malformations, and gestational age. Unique personal

Full Text available with Trip Pro

2015 JAMA

160. Sulthiame add-on therapy for epilepsy. (PubMed)

Sulthiame add-on therapy for epilepsy. Epilepsy is a common neurological condition characterised by recurrent seizures. Most patients respond to conventional antiepileptic drugs, however, around 30% will continue to experience seizures despite multiple antiepileptic drugs. Sulthiame, also known as sultiame, is a widely used antiepileptic drug in Europe and Israel. We present a summary of the evidence for the use of sulthiame as add-on therapy in epilepsy.To compare the efficacy and side-effect (...) profile of sulthiame as add-on therapy compared with placebo or another antiepileptic drug.We searched the Cochrane Epilepsy Group's Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, ClinicalTrials.gov and the WHO ICTRP Search Portal on 11 August 2015. No language restrictions were imposed. We contacted the manufacturers of sulthiame and researchers in the field to seek any ongoing or unpublished studies.Randomised controlled add-on trials of sulthiame

2015 Cochrane